BioPharma Credit PLC BPCR.L
Composite 68/100; the shares have moved about 10% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Its least supportive area is Growth at 51 — still above average.
Income ranks 80/100 — a strong point in its favour. Balance-sheet strength ranks 77/100 — a strong point in its favour. Quality ranks 72/100 — a moderate point in its favour.
Its least supportive area is Growth at 51 — still above average.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.